Navigation Links
Precision Economy Incubators 3EM

ProductsPrecision Economy Incubators 3EM
Company Precision Medical, Inc.
Item Precision Economy Incubators 3EM
Features Broad temperature range, excellent temperature control. Small footprint, large capacity. Simple to maintain. UL listed.
Description Precision Economy Incubators available in five different models. Choose mechanical or gravity convection; capacities of 1.4 cu. Ft. (39 liters), 2.5 cu. Ft. (71.5 liters), or 4.5 cu. ft. (129 liters. Equally important, Precision Economy Incubators combine a wide temperature range with excellent temperature sensitivity, stability, and uniformity. As a result, you will find them ideal for a broad range of applications. It is also designed to help you conserve precious bench space, packing up to 11.5 sq. ft. (1.0 sq. m.). Plus they come equipped with a standard cord so you can have them up and operating in your lab in just minutes.
Info Precision Medical, Inc.
Customer Service: (800) 272-7285
Web site: http://www.precisionmedical.com

Related medicine products :

1. Precisionist Phacoemulsification System
2. Precision Programmable Autoclaves
3. Precision Economy Incubators 5EM
4. Precision Economy Incubators 2EG
5. Precision Economy Incubators 3EG
6. Precision Economy Incubators 5EG
7. Pocket II Precision Pachymeter
8. Precision Xtra Advanced Diabetes Tester
9. Precision Net
10. Precision PCx® Point-of-Care System
11. Precision Hand Instrumentation: 3.4mm Low Profile
The Omni-Flex System provides the capability to change frame arms in the middle of surgery while retaining exposure with tension on the incision. The system is also strong enough to be stable for lar
...actor System represents the most widely accepted "...array of retraction components provides numerous s...lti-directional exposure of the surgical field. In...pecific procedures: IMA Kit / Bariatric Kit / Spin...
...he Alexis Wound Retractor provides circumferential...ination. For open surgery, the Alexis Retractor pr...ion size. For laparoscopic surgery, the Alexis Ret...protection when an organ or specimen requires remo...
Pipetman Concept is a revolutionary motorized electronic pipette. Conceived with simplicity and flexibility in mind, Pipetman Concept features exclusive multifunction characteristics and a direct pip
Medicine Products:
(Date:10/7/2008)...post-HAART era , , TUESDAY, Oct. 7 (Heal... finds little evidence that circumcision protects ...e issue is still far from settled. , For one th...l AIDS drugs showed that circumcision did have a p... the most definitive type of research into the eff...
(Date:10/7/2008)...Salud Primero to teach ABCs of ...t. 7 /PRNewswire/ -- Lifelink today announced that...comprehensive diet and,nutrition curriculum to all... in an effort to have a dramatic impact on lowerin...ren. Lifelink also will offer the,program in home-...
(Date:10/7/2008)...chers have developed a magnetic resonance imaging ...njury to the wall of the heart,s left atrium in pa...ial fibrillation. The results of the study are pub...of the American College of Cardiology . , Atria...heart rhythm, that involves the heart,s two upper ...
(Date:10/7/2008)...choices for Indiana healthcare ...RNewswire/ -- Lutheran Health Network (LHN),announ...mers Life Insurance,Company forming a new network ...ndiana counties including the Fort Wayne area., I...ne,s Lutheran,Hospital, the region,s only heart-tr...
Breaking Medicine News(10 mins):Health News:Role of Circumcision in Reducing HIV Risk Still Unclear 2Health News:DuPage's Only Provider of Head Start Takes Aim at Childhood Obesity in Minorities 2Health News:DuPage's Only Provider of Head Start Takes Aim at Childhood Obesity in Minorities 3Health News:Novel imaging approach may assist in predicting success of treatment for atrial fibrillation 2Health News:Consumers Life Expands Healthcare Network in Northeast Indiana 2
...earcher at Tulane University, Marie Krousel-Wood s... were three times less likely taking blood pressur...sit //clinics are 2 times more likely to report le...now that only one in three people with high blood ...
...a major Ranbaxy Laboratories Ltd has entered into ...maceuticals Inc for marketing Zonisamide Capsules ... in the US market. Under the agreement products wo...roval to the USFDA. Ranbaxy Pharmaceuticals Inc wo...
...octors in Toronto are desperately trying to reatta...st his foot in a freak accident that involved his ...ing to York Region police the boys father had been... up unexpectedly behind him. Constable Laurie Perk...
...hird of the people who are undergoing fertility t...he treatment because they are apprehensive // abou...e Infertility Network of the UK on approximately... were worried about not being able to gain the sym...
Other Medicine News:
(Date:10/6/2008)...llaborate to Improve Patient Safety, WASHINGTON, ...lege of,Cardiology in collaboration with the Ameri...eart Association today released consensus guidelin...risk of ulcers and,gastrointestinal (GI) bleeding ...y drugs (NSAIDs) along with antiplatelet agents., ...
(Date:10/6/2008)...ICADE Therapy is More Likely to Induce Steroid-F...andard Immunomodulator, Azathi...a presented for the first time,from the Phase 3b S...unomodulators and Biologic Therapy (SONIC) may pro...ients with moderate to severe Crohn,s disease.,Acc...
(Date:10/6/2008)...e to severe patients achieved endoscopic,response ...sion at Week 10,in data from a 54-week open-label ...nterology (ACG) Annual Scientific Meeting, ORLAND...d data from a,large, prospective study investigati...with a biologic compound. The data presented at th...
(Date:10/6/2008)...ate 6 Weeks of Radiation Therapy -, Event: Watch S...ednesday, October 22, 2008, 3 - 4 p.m. by visit...ON, Va., Oct. 6 / Questions raced thr...breast cancer in May. Would she have the,tumor rem...chemotherapy?, , To view the Multimedia News Rel...
Breaking Medicine Technology:Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use 2Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use 3Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use 4New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 2New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 3New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 4New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 5New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 6New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 7New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 8CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 2CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 3CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 4CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 6CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 7Photos: Sentara Joins 4 U.S. Hospitals in International 'TARGIT' Breast Cancer Trial 2Warner Chilcott to Present at the 2008 Wachovia Healthcare Conference 10071 1Align Technology Launches Aligntech Institute to Help Invisalign Providers Enhance Treatment Success and Practice Economics 10067 1Align Technology Launches Aligntech Institute to Help Invisalign Providers Enhance Treatment Success and Practice Economics 10067 2Align Technology Launches Aligntech Institute to Help Invisalign Providers Enhance Treatment Success and Practice Economics 10067 3Global Sales Veteran Jack McGovern Joins MediKeeper 10065 1Global Sales Veteran Jack McGovern Joins MediKeeper 10065 2AIDS Healthcare Foundation Hosts Grand Opening of Wilton Manors Out of the Closet 26 AHF Pharmacy 10061 1AIDS Healthcare Foundation Hosts Grand Opening of Wilton Manors Out of the Closet 26 AHF Pharmacy 10061 2AIDS Healthcare Foundation Hosts Grand Opening of Wilton Manors Out of the Closet 26 AHF Pharmacy 10061 3
...e/ -- Southern,Research Institute, a not-for-profi...earch in the areas of preclinical drug,discovery a...tists,will be delivering one oral presentation and...ciation for Cancer Research,(AACR) Annual Meeting,... Roy of Southern Research will be presenting new,d...
...WSWIRE) -- New data,presented at ECCMID highlight ...f Basilea,s (SWX:BSLN) two late-stage,drug candida...ed,both for ceftobiprole, the first anti-MRSA broa..., and for isavuconazole, a,novel azole for the tre...her data on their respective breadths of spectrum,...
Other Medicine Technology:Southern Research Institute to Present at the 2007 American,Association For Cancer Research Annual Meeting 2Southern Research Institute to Present at the 2007 American,Association For Cancer Research Annual Meeting 3Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 2Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 3Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 4Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 5Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 6Scientific Results Presented At ECCMID Demonstrate Well-,Differentiated Profile of Basilea's Two Phase III Anti- infective,Compounds 7